Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

136.90 -4.08 (-2.89%)
Official Closing Price Updated: 7:00 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Charles River Laboratories Announces Opening of U.K. Manufacturing Facility
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A
From Charles River Laboratories International, Inc.
Via Business Wire
Analyst Ratings for Charles River
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings: 
Via Benzinga
Charles River: Q1 Earnings Insights
Charles River (NYSE:CRL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: Charles River Q4 Earnings
  Charles River (NYSE:CRL) reported its Q4 earnings results on Wednesday, February 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Charles River Laboratories to Participate in Jefferies and William Blair Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022
Upgrades 
Via Benzinga
Earnings Scheduled For February 16, 2022
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million. 
Via Benzinga
Charles River Laboratories Announces First-Quarter 2022 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Preview: Charles River's Earnings
Charles River (NYSE:CRL) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Charles River... 
Via Benzinga
Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets
From Charles River Laboratories International, Inc.
Via Business Wire
3 Top S&P 500 Stock Market Gainers Today: Coronavirus Vaccine Maker Moderna Jumps
Moderna led big-cap winners Monday. Oil services giants were losers. 
Via Investor's Business Daily
Wells Fargo Maintains Overweight Rating for Charles River: Here's What You Need To Know
Wells Fargo has decided to maintain its Overweight rating of Charles River (NYSE:CRL) and lower its price target from $390.00 to $325.00. Shares of Charles River are trading down 7.96% over the last 24... 
Via Benzinga
What 6 Analyst Ratings Have To Say About Charles River
Analysts have provided the following ratings for Charles River (NYSE:CRL) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
10 Biggest Price Target Changes For Monday
Keybanc cut Salesforce, Inc. (NYSE: CRM) price target from $281 to $223. Salesforce shares fell 1.1% to $169.60 in pre-market trading. 
Via Benzinga
Charles River Laboratories Schedules First-Quarter 2022 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Publishes 2021 Corporate Citizenship Report
From Charles River Laboratories International, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2022
Upgrades 
Via Benzinga
Charles River Buys Contract Vivarium Research Services Firm In $295M Deal
Charles River Laboratories International Inc (NYSE: CRL) has acquired Explora BioLabs Holdings Inc, a provider of contract vivarium research services,  
Via Benzinga
Charles River Laboratories Acquires Explora BioLabs
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Appoint Flavia H. Pease as Chief Financial Officer
From Charles River Laboratories International, Inc.
Via Business Wire
Markets Fall Amid Rising Oil Prices
U.S. indices finished lower Wednesday as investors continue to weigh the Federal Reserve tapering outlook, inflation concerns and the Russia-Ukraine war. Oil prices have also... 
Via Benzinga
Inflation Beneficiary ETFs in Focus as Prices Soar
Many experts predicted that inflation would cool off in spring as supply chains improve after pandemic-driven disruptions. It now appears that higher inflation could persist for longer. 
Via Talk Markets
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature. 
Via InvestorPlace
Charles River Earnings Perspective: Return On Invested Capital
According to Benzinga Pro, during Q4, Charles River (NYSE:CRL) earned $139.83 million, a 32.97% increase from the preceding quarter. Charles River also posted a total of $905.05 million in sales, a... 
Via Benzinga
10 Biggest Price Target Changes For Thursday
Cowen & Co. raised Yum! Brands, Inc. (NYSE: YUM) price target from $134 to $143. Yum! Brands shares fell 0.3% to $123.00 in pre-market trading. Keybanc cut the price target... 
Via Benzinga
Charles River's Q4 Earnings Beats Street Expectation, Reaffirms FY22 Outlook
Charles River Laboratories International Inc's (NYSE: CRL)  
Via Benzinga
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.